Table A4.
Association Between Blood Circulating Biomarker Levels in Hearing Responders (n = 5) Versus Nonresponders (n = 8) Treated With Bevacizumab
| Biomarker | Median (IQR) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (pg/ml), n=13 | Percent Change | |||||||
| Week 25 (n = 13) | Week 49 (n = 12) | Week 72 (n = 11) | ||||||
| Responders (n = 5) | Nonresponders (n = 8) | Responders (n = 5) | Nonresponders (n = 8) | Responders (n = 5) | Nonresponders (n = 7) | Responders (n = 4) | Nonresponders (n = 7) | |
| sVEGFR2 | 10,691 (8,417-11,108) | 11,739 (9,911-13,842) | 1.06 (1.05-1.21) | 0.93 (0.87-0.93) | 1.03 (0.93-1.07) | 0.88 (0.85-1.01) | 1.13 (1.01-1.18) | 0.87 (0.84-0.90) |
| P | .19 | .0043 | .074 | .014 | ||||
| HGF | 745 (602-821) | 957 (841-1,054) | 1.11 (1.03-1.20) | 0.92 (0.86-1.21) | 1.23 (1.05-1.38) | 1.03 (0.99-1.22) | 1.03 (1.03-1.19) | 1.12 (0.85-1.17) |
| P | .019 | .092 | .42 | .65 | ||||
| CAIX | 50 (47-71) | 32 (20-51) | 0.72 (0.54-0.75) | 2.04 (1.40-2.32) | 0.59 (0.51-0.69) | 1.81 (1.49-2.63) | 0.95 (0.64-1.16) | 1.67 (1.11-2.01) |
| P | .14 | .010 | .035 | .12 | ||||
NOTE. Bold font indicates statistical significance.
Abbreviations: CAIX, carbonic anhydrase IX; HGF, hepatocyte growth factor; IQR, interquartile range; sVEGFR, soluble vascular endothelial growth factor receptor.